DSS, INC. (DSS) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended March 31, 2026. DSS, Inc. operates four distinct business lines: Product Packaging (Premier Packaging), Biotechnology (Impact BioMedical), Commercial Lending (American Pacific Financial), and Securities and Investment Management (including a REIT). The company is a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $4,331,000 | $4,954,000 |
| Net Loss | $(6,354,000) | $(5,296,000) |
| Net Loss Attributable to Common Stockholders | $(5,819,000) | $(4,777,000) |
| Operating Loss | $(5,487,000) | $(3,726,000) |
| Cash and Cash Equivalents (End of Period) | $4,936,000 | $10,975,000 |
| Net Cash Used in Operating Activities | $(133,000) | $168,000 (Provided) |
| Total Debt (Current + Long-Term) | ~$36.0M | ~$36.1M |
| Stockholders' Equity | $12,545,000 | $29,821,000 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 13% year-over-year. While Product Packaging revenue grew 4% to $4.16M, Securities revenue plummeted 83% (driven by a tenant vacancy at the Pittsburgh facility and lower commission income), and Commercial Lending revenue dropped 71% due to loans moving to non-accrual status.
- Increased Losses: Net loss increased 20% to $6.35M. This was driven by the revenue decline and a significant increase in stock-based compensation ($1.44M in Q1 2026 vs. $872K in Q1 2025) related to grants at Impact BioMedical.
- Investment Activity: The company recorded a $700,000 loss on investments and a $128,000 loss on the change in fair value of a related-party convertible bond. Conversely, the prior year included a $684,000 loss on the sale of real estate which did not recur.
- Debt Status: A significant portion of the company's debt portfolio is in default or non-accrual, including the LifeCare Agreement ($30.3M outstanding, past due since Dec 2023) and several related-party notes.
Outlook, Risks, and Contingencies
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern due to recurring operating losses and negative cash flows. The company relies on equity/debt financing and asset sales to meet liquidity needs.
- Related Party Transactions: Significant activity includes a $2.45M convertible note issued to Alset International Limited (related party) and the receipt of a $2.45M convertible bond from True Partners Capital (related party), which was recorded at a fair value of $8.52M, resulting in a $6.2M capital contribution.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting that remained unremediated as of March 31, 2026.
- Merger Status: A pending merger with Impact BioMedical and Dr Ashleys is subject to regulatory approval, with the closing date extended to July 1, 2026.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $4.9M cash balance against the $30.3M past-due LifeCare debt and ongoing operating burn rate.
- Debt Covenants: Confirm the status of the LifeCare Agreement default and whether any acceleration clauses have been triggered by the lender.
- Related Party Valuations: Scrutinize the $8.52M fair value assigned to the True Partners convertible bond and the $6.2M capital contribution, given the Level 3 classification and lack of active market pricing.
- Stock-Based Compensation: Assess the sustainability of the $1.44M stock-based expense incurred in Q1 2026 and its impact on future dilution.
- Non-Accrual Loans: Review the specific borrowers in the Commercial Lending portfolio that have moved to non-accrual status and the adequacy of the $7.5M loan loss reserve.